期刊
CLINICAL INFECTIOUS DISEASES
卷 62, 期 4, 页码 484-490出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/civ911
关键词
tuberculosis; fluoroquinolones; shortening regimen; REMox-TB; OFLOTUB
资金
- NIAID NIH HHS [P30 AI094189] Funding Source: Medline
The disappointing recent failure of fluoroquinolone-containing regimens to shorten the duration of tuberculosis treatment in costly phase 3 trials has raised serious questions about the reliability of preclinical tuberculosis models, especially mice, and the current paradigm of regimen development. Therefore we re-examined data from murine models and early-stage clinical trials on which the pivotal trials were based, concluding that phase 3 trial results were in line with preceding studies. Finally, we offer suggestions for a more efficient and integrated preclinical and clinical regimen development program where quantitative pharmacokinetic and pharmacodynamic models more predictive of curative treatment durations are set forth.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据